

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## Hansoh Pharmaceutical Group Company Limited

### 翰森製藥集團有限公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 3692)**

## VOLUNTARY ANNOUNCEMENT

### CLINICAL TRIAL NOTICE OF “HS-20117”

As disclosed in the announcement of Hansoh Pharmaceutical Group Company Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) dated November 14, 2022, Hansoh (Shanghai) Healthtech Company Limited\* (翰森(上海)健康科技有限公司), a wholly-owned subsidiary of the Company, obtained an exclusive license from Biotheus Inc.\* (“**Biotheus**”) to develop and commercialize PM1080 within China (including Hong Kong, Macau and Taiwan).

The board of directors (the “**Board**”) of the Company is pleased to announce that “HS-20117” (license-in as PM1080), a Category 1 innovative drug developed by the Group under the license from Biotheus, has been granted a clinical trial notice issued by the National Medical Products Administration of the People’s Republic of China, and is intended to be used for the treatment of advanced solid tumor.

#### **ABOUT HS-20117 (PM1080)**

HS-20117 is an EGFR/cMet bispecific anti-body drug with therapeutic potential to block both EGFR and c-Met signaling, inhibit tumor growth and survival, etc.

By Order of the Board  
**Hansoh Pharmaceutical Group Company Limited**  
**Zhong Huijuan**  
*Chairlady*

Hong Kong, June 5, 2023

*As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Ms. Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.*

\* for identification purposes only